Browse IL16

Summary
SymbolIL16
Nameinterleukin 16
Aliases LCF; IL-16; prIL-16; HsT19289; FLJ42735; FLJ16806; prointerleukin 16; lymphocyte chemoattractant factor; int ......
Chromosomal Location15q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Interleukin-16: Secreted.; SUBCELLULAR LOCATION: Isoform 1: Cytoplasm ; SUBCELLULAR LOCATION: Isoform 3: Cytoplasm. Nucleus.
Domain PF00595 PDZ domain (Also known as DHR or GLGF)
Function

Interleukin-16 stimulates a migratory response in CD4+ lymphocytes, monocytes, and eosinophils. Primes CD4+ T-cells for IL-2 and IL-15 responsiveness. Also induces T-lymphocyte expression of interleukin 2 receptor. Ligand for CD4.; FUNCTION: Isoform 1 may act as a scaffolding protein that anchors ion channels in the membrane.; FUNCTION: Isoform 3 is involved in cell cycle progression in T-cells. Appears to be involved in transcriptional regulation of SKP2 and is probably part of a transcriptional repression complex on the core promoter of the SKP2 gene. May act as a scaffold for GABPB1 (the DNA-binding subunit the GABP transcription factor complex) and HDAC3 thus maintaining transcriptional repression and blocking cell cycle progression in resting T-cells.

> Gene Ontology
 
Biological Process GO:0030595 leukocyte chemotaxis
GO:0032103 positive regulation of response to external stimulus
GO:0040017 positive regulation of locomotion
GO:0050900 leukocyte migration
GO:0050918 positive chemotaxis
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0050926 regulation of positive chemotaxis
GO:0050927 positive regulation of positive chemotaxis
GO:0050930 induction of positive chemotaxis
GO:0060326 cell chemotaxis
Molecular Function GO:0005125 cytokine activity
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-449147: Signaling by Interleukins
Summary
SymbolIL16
Nameinterleukin 16
Aliases LCF; IL-16; prIL-16; HsT19289; FLJ42735; FLJ16806; prointerleukin 16; lymphocyte chemoattractant factor; int ......
Chromosomal Location15q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IL16 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IL16 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26139534MelanomaInhibit immunity (T cell function)Therefore, the melanoma microenvironment contributes to skewing of CD8 T cell differentiation programs, in part by TGFβ/IL-6-mediated induction of Maf.
Summary
SymbolIL16
Nameinterleukin 16
Aliases LCF; IL-16; prIL-16; HsT19289; FLJ42735; FLJ16806; prointerleukin 16; lymphocyte chemoattractant factor; int ......
Chromosomal Location15q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IL16 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIL16
Nameinterleukin 16
Aliases LCF; IL-16; prIL-16; HsT19289; FLJ42735; FLJ16806; prointerleukin 16; lymphocyte chemoattractant factor; int ......
Chromosomal Location15q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IL16 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1680.686
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.6850.56
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.7910.38
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1950.634
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.3270.875
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0310.99
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2260.628
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8850.571
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.5440.761
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.4030.304
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.240.569
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3320.0648
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IL16 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.78.2-4.50.671
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.710.2-6.50.425
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.811.8-70.577
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.718.2-10.50.576
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIL16
Nameinterleukin 16
Aliases LCF; IL-16; prIL-16; HsT19289; FLJ42735; FLJ16806; prointerleukin 16; lymphocyte chemoattractant factor; int ......
Chromosomal Location15q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IL16. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIL16
Nameinterleukin 16
Aliases LCF; IL-16; prIL-16; HsT19289; FLJ42735; FLJ16806; prointerleukin 16; lymphocyte chemoattractant factor; int ......
Chromosomal Location15q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IL16. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IL16.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIL16
Nameinterleukin 16
Aliases LCF; IL-16; prIL-16; HsT19289; FLJ42735; FLJ16806; prointerleukin 16; lymphocyte chemoattractant factor; int ......
Chromosomal Location15q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IL16. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIL16
Nameinterleukin 16
Aliases LCF; IL-16; prIL-16; HsT19289; FLJ42735; FLJ16806; prointerleukin 16; lymphocyte chemoattractant factor; int ......
Chromosomal Location15q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IL16 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIL16
Nameinterleukin 16
Aliases LCF; IL-16; prIL-16; HsT19289; FLJ42735; FLJ16806; prointerleukin 16; lymphocyte chemoattractant factor; int ......
Chromosomal Location15q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IL16 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIL16
Nameinterleukin 16
Aliases LCF; IL-16; prIL-16; HsT19289; FLJ42735; FLJ16806; prointerleukin 16; lymphocyte chemoattractant factor; int ......
Chromosomal Location15q26.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IL16 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.